Welcome to our dedicated page for AKTIS ONCOLOGY news (Ticker: AKTS), a resource for investors and traders seeking the latest updates and insights on AKTIS ONCOLOGY stock.
Aktis Oncology, Inc. (Nasdaq: AKTS) is a clinical-stage oncology company focused on targeted radiopharmaceuticals for solid tumors, and its news flow reflects this specialization. Company announcements emphasize progress in its miniprotein radioconjugate platform, which is designed to deliver radioisotopes selectively to tumors while limiting exposure to normal tissues.
News related to Aktis Oncology includes capital markets milestones, such as the closing of its upsized initial public offering and the start of trading on the Nasdaq Global Select Market under the AKTS ticker. These updates provide context on how the company is financing its research and development activities in targeted alpha radiopharmaceuticals.
Investors and observers can also expect coverage of pipeline developments. Aktis Oncology has highlighted programs such as AKY-1189 and AKY-2519, as well as its most advanced program targeting Nectin-4 with a miniprotein radioconjugate that it describes as having multi-indication potential across multiple tumor types. News may discuss clinical progress, platform refinements, and efforts to expand the reach of its radiopharmaceutical candidates to larger patient populations.
Another recurring theme in Aktis Oncology news is its strategic collaboration with Eli Lilly and Company, which is intended to apply the company’s miniprotein platform to novel radioconjugates outside its proprietary pipeline. Updates may reference how this collaboration fits into the company’s broader strategy.
For readers following AKTS, the news page offers a way to track developments in its clinical programs, financing events, and partnership activities over time. Regularly reviewing this coverage can help provide a clearer picture of how the company’s radiopharmaceutical platform and solid tumor pipeline are evolving.
Akoustis Technologies, Inc. (NASDAQ: AKTS) is set to attend multiple investor conferences in June 2022. Key dates include the 19th Annual Craig-Hallum Institutional Investor Conference on June 1, the Loop Capital Markets Annual Investor Conference on June 2, and the UBS Future of 5G Day on June 3. The Stifel 2022 Cross Sector Insight Conference is scheduled for June 8, featuring a presentation by management. Lastly, the 8th Annual ROTH London Conference will run from June 21-23. Akoustis is increasing its production capacity to approximately 500 million filters annually in response to strong market demand.
Akoustis Technologies, Inc. (NASDAQ: AKTS) announced that CEO Jeffrey Shealy will present at the 2022 CS MANTECH Conference on May 11, 2022, at 1:40 pm PT. The presentation will focus on the company’s advancements in Single Crystal AlScN-on-Silicon XBAW RF Filter Technology for 5G and Wi-Fi 6E applications. Akoustis aims to increase production capacity to 500 million filters per year due to rising demand for its patented solutions. The company has secured over 20 customer design wins and is actively shipping various filters for mobile and wireless markets.
Akoustis Technologies, Inc. (NASDAQ: AKTS) announced its participation in the 7th Annual Oppenheimer Emerging Growth Conference scheduled for May 10, 2022. Senior management will present virtually due to ongoing pandemic concerns. Investors can access the presentation on Akoustis' investor website. The company is experiencing increased demand, actively producing Wi-Fi 6 solutions and expanding its New York facility's production capacity to approximately 500 million filters annually. Akoustis has secured over 20 design wins for its XBAW™ filter solutions, reinforcing its position in the high-tech RF filter market.
Akoustis Technologies (NASDAQ: AKTS) has successfully shipped its second of two filters for a tier-1 5G mobile RF component customer. These filters, developed to solve 5G/Wi-Fi coexistence issues, are part of Akoustis's proprietary wafer-level-package (WLP) technology. The first filter's production is set to ramp up in early CY23. The company has received over 20 customer design wins and aims to increase its annual production capacity to approximately 500 million filters at its New York facility, targeting the rapidly growing 5G mobile device market.
Akoustis Technologies, Inc. (NASDAQ: AKTS) reported record revenue of $4.6 million for Q3 FY22, a 25% increase sequentially. The growth was driven by XBAW™ filter sales, with expectations for over 30% sequential growth in Q4 FY22. As of March 31, 2022, the company held $55.9 million in cash. Akoustis successfully integrated RFMi, expanding its product portfolio. The company sees robust customer demand in 5G and Wi-Fi markets, adding new design wins and customers. Despite improvements, the net loss was $14.7 million due to high operating expenses.
Akoustis Technologies, Inc. (NASDAQ: AKTS) announced two new Wi-Fi 6E design wins, expanding its customer base from three to fifteen within six months. The first design win involves an enterprise-class router expected to ramp production in December 2022, utilizing four XBAW™ filters. The second win is for a consumer router, set to begin production in September 2022 with multiple XBAW™ filters per device. Akoustis is increasing its New York manufacturing capacity to approximately 500 million XBAW™ filters annually to meet growing demand.
Akoustis Technologies (NASDAQ: AKTS) plans to webcast its Q3FY22 results on May 2, 2022, at 8:00 am ET. Following the results, management will host a Q&A session. Investors can listen via phone or through the company's website. Akoustis is expanding its production capacity to 500 million filters annually, driven by demand for its Wi-Fi 6 and 5G RF filter solutions. The company has actively shipped various filters and is focused on growing its market in the multi-billion dollar RF filter sector.
Akoustis Technologies, Inc. (NASDAQ: AKTS) has announced that its Founder and CEO, Jeff Shealy, will present at the 34th Annual Roth Conference from March 13-15, 2022, in Orange County, CA. Shealy's presentation is scheduled for March 14 at 2:30 pm PT and will be webcast live on the company’s investor website. Akoustis is ramping up its production capacity to 500 million filters per year to meet the growing demand for its Wi-Fi 6 and 5G technologies. The company is currently delivering multiple filter solutions and actively engaging with customers to enhance its market position.
Akoustis Technologies (NASDAQ: AKTS) announced its participation in the 11th Annual Susquehanna Technology Conference, set for March 3-4, 2022. Due to Covid-19, meetings will occur virtually, and interested investors can contact Akoustis' investor relations. The company continues its growth by delivering Wi-Fi 6 filter solutions and increasing production capacity at its New York facility to 500 million filters annually to meet rising demand for 5G and Wi-Fi technologies in 2022.
Akoustis Technologies (NASDAQ: AKTS) has secured a development order for a new 5G mobile XBAW filter from a tier-1 RF module maker. This new filter will enhance 5G RF front-end modules, utilizing Akoustis’ proprietary XBAW process and in-house wafer-level packaging (WLP) capabilities. The company is also ramping up production capacity to approximately 500 million filters annually to meet growing demand in the 5G and Wi-Fi markets. CEO Jeff Shealy highlights the order's significance in addressing high-volume mobile band requirements.